ME01320B - Derivati citokina - Google Patents

Derivati citokina

Info

Publication number
ME01320B
ME01320B MEP-2011-47A MEP4711A ME01320B ME 01320 B ME01320 B ME 01320B ME P4711 A MEP4711 A ME P4711A ME 01320 B ME01320 B ME 01320B
Authority
ME
Montenegro
Prior art keywords
polypeptide
nucleic acid
diseases
host cell
indicated
Prior art date
Application number
MEP-2011-47A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Olivier Hartley
Original Assignee
The Mintaka Medical Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mintaka Medical Res Foundation filed Critical The Mintaka Medical Res Foundation
Publication of ME01320B publication Critical patent/ME01320B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
MEP-2011-47A 2006-07-25 2007-07-25 Derivati citokina ME01320B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
EP07825334A EP2076532B1 (en) 2006-07-25 2007-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (1)

Publication Number Publication Date
ME01320B true ME01320B (me) 2013-12-20

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-47A ME01320B (me) 2006-07-25 2007-07-25 Derivati citokina

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
CN112469429B (zh) * 2018-05-28 2025-02-14 奥立安生物技术瑞士有限责任公司 Ccr5抑制剂在癌症治疗中的应用
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164818C (en) * 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US20030049603A1 (en) * 2001-09-05 2003-03-13 Guy Gorochov Methods for construction and screening of libraries of chemokine variants
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Also Published As

Publication number Publication date
CA2658806C (en) 2017-01-03
ATE490270T1 (de) 2010-12-15
CN101511867A (zh) 2009-08-19
AU2007278894A1 (en) 2008-01-31
US20090317363A1 (en) 2009-12-24
US20130330305A1 (en) 2013-12-12
JP2009544304A (ja) 2009-12-17
PL2076532T3 (pl) 2011-07-29
SI2076532T1 (sl) 2011-06-30
RU2461567C2 (ru) 2012-09-20
CN101511867B (zh) 2014-04-09
DE602007010969D1 (de) 2011-01-13
RU2009106436A (ru) 2010-08-27
HRP20110146T1 (hr) 2011-06-30
KR20090060281A (ko) 2009-06-11
RS51854B (sr) 2012-02-29
MX2009000918A (es) 2009-08-26
EP2076532B1 (en) 2010-12-01
HK1131162A1 (en) 2010-01-15
GB0614755D0 (en) 2006-09-06
BRPI0715331B1 (pt) 2021-04-13
WO2008012689A3 (en) 2008-05-08
WO2008012689A2 (en) 2008-01-31
BRPI0715331B8 (pt) 2021-05-25
AU2007278894B2 (en) 2012-08-09
BRPI0715331A2 (pt) 2013-07-16
DK2076532T3 (da) 2011-03-07
CY1111630T1 (el) 2015-10-07
CA2658806A1 (en) 2008-01-31
JP5224603B2 (ja) 2013-07-03
KR101530353B1 (ko) 2015-06-26
ZA200901342B (en) 2010-11-24
PT2076532E (pt) 2011-03-02
NZ575092A (en) 2011-08-26
EP2076532A2 (en) 2009-07-08
ES2361455T3 (es) 2011-06-17
US9328153B2 (en) 2016-05-03
US8686111B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
ME01320B (me) Derivati citokina
Nguyen et al. Immunostimulating and Gram‐negative‐specific antibacterial cyclotides from the butterfly pea (Clitoria ternatea)
Strålberg et al. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
Sun et al. A novel cathelicidin from Bufo bufo gargarizans Cantor showed specific activity to its habitat bacteria
HRP20110368T1 (hr) Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
CN103030687B (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
JP2006506942A5 (enExample)
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
JP2009544304A5 (enExample)
MX341317B (es) Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
Lohani et al. Dichotomous life of DNA binding high mobility group box1 protein in human health and disease
JP2023517616A (ja) 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
Il’in et al. Analysis of IL-1α, bFGF, TGF-β1, IFNγ, MMP-1, and CatD expression in multinuclea macrophages in vitro
JP2017519763A5 (enExample)
US8815812B2 (en) Synthetic arginine substituted peptides and their use
CN102115495B (zh) 胶原靶向治疗增生性瘢痕蛋白药物的制备及应用
JP2011503008A5 (enExample)
CN102241748B (zh) D29分枝杆菌噬菌体来源的pk34多肽及其应用
CN102574893A (zh) 新的抗致病肽
CN115003686A (zh) 用于抗冠状病毒感染的药物及其应用
JP2020519623A (ja) メトトレキサートとペプチドの結合体
GB201018125D0 (en) Peptide